Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v18.i6.40
16 pages

In Vivo Applications of PEG Liposomes: Unexpected Observations

Peter Laverman
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Otto C. Boerman
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Wim J. G. Oyen
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Frans H. M. Corstens
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Gert Storm
Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, The Netherlands

RÉSUMÉ

Recent studies with PEG liposomes in patients have consistently shown that liposomes can induce side effects (flushing, tightness of the chest). Furthermore, the blood clearance of PEG liposomes was shown to be dose-dependent: at lipid doses lower than 1 mmol/kg, PEG liposomes do not show the long-circulation property but instead are cleared relatively rapidly from the bloodstream. Another remarkable observation was that repeated injections of PEG liposomes led to significant pharmacokinetic changes: the circulatory half-life of a second dose of radiolabeled PEG liposomes dramatically decreased when given from 5 days to up to 4 weeks after a first injection. In these three unexpected phenomena, proteins of the complement system seem to play a key role.Therefore, one has to consider that PEG liposomes are not inert drug-carrying vehicles in vivo. Pharmacological effects can occur, induced solely by using liposomal particles irrespective of the drug content.


Articles with similar content:

The Role of Inflammation,Oxidative Stress, and Proliferation in Silica-Induced Lung Disease: A Species Comparison
Journal of Environmental Pathology, Toxicology and Oncology, Vol.20, 2001, issue Suppl.1
Janet M. Carter, Kevin E. Driscoll
Poly (ADP-Ribose) Polymerase and DNA-Dependent Protein Kinase: Differential Activation In Vivo
Journal of Environmental Pathology, Toxicology and Oncology, Vol.23, 2004, issue 1
Himanshi Narang, Naresh C. Verma, Malini Krishna
Polymeric Micelles for Delivery of Poorly Water-Soluble Compounds
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 5
Glen S. Kwon
The Cyclooxygenase-2 Inhibitor Etoricoxib Is a Potent Chemopreventive Agent of Colon Carcinogenesis in the Rat Model
Journal of Environmental Pathology, Toxicology and Oncology, Vol.28, 2009, issue 1
Sankar Nath Sanyal, Manpreet Kaur Saini, Pinky Sharma, Jasmeet Kaur
Caffeine Potentiation of Allyl Alcohol-Induced Hepatotoxicity. II. In Vitro Study*
Journal of Environmental Pathology, Toxicology and Oncology, Vol.20, 2001, issue 2
Maria Karas, Saroj K. Chakrabarti